Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H2 synthases by ibuprofen, naproxen, and indomethacin

Biochemical Pharmacology

Volumn 62, Issue 12, 2001, Pages 1587-1595

  Jaradat, Maisa S ^a   Wongsud, Buanus ^b   Phornchirasilp, Srichan ^b   Rangwala, Shamina M ^c   Shams, Gamal ^c   Sutton, Melissa ^d   Romstedt, Karl J ^d   Noonan, Daniel J ^e   Feller, Dennis R ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c OHIO STATE UNIVERSITY   (United States)

^d CAPITAL UNIVERSITY   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Ibuprofen isomers; Naproxen; Nonsteroidal anti inflammatory drugs; Peroxisome proliferator activated receptors; Prostaglandin endoperoxide H synthases

Indexed keywords

ARACHIDONIC ACID; FATTY ACID BETA OXIDASE; IBUPROFEN; INDOMETACIN; NAPROXEN; OXIDOREDUCTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE 1; PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE 2; PROSTAGLANDIN SYNTHASE; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE; STEREOCHEMISTRY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; IBUPROFEN; INDOMETHACIN; NAPROXEN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEIN ISOFORMS; RATS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0035894284     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(01)00822-X     Document Type: Article

References (53)

1. Analgesic-antipyretics, and anti-inflammatory agents: Drugs employed in the treatment of rheumatoid arthritis, and gout
2. Nonsteroidal anti-inflammatory drugs
3. Predictability of the clinical potency of NSAIDs from the preclinical pharmacodynamics in rats
4. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes
5. Cloning two isoforms of rat cyclooxygenase: Differential regulation of their expression
6. The eicosanoids and their biochemical mechanisms of action
7. Pharmacology of prostaglandin endoperoxide synthase isozymes-1 and -2. A review
8. Cloning and expression of rat prostaglandin endoperoxide synthase (cyclooxygenase)-2 cDNA
9. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines
10. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
11. Lipopolysaccharide priming of alveolar macrophages for enhanced synthesis of prostanoids involves induction of a novel prostaglandin H synthase
12. Multiple sites on prostaglandin cyclooxygenase are determinants in the action of nonsteroidal anti-inflammatory agents
13. Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs
14. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic, and antipyretic effects, which causes minimal stomach lesions
15. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthetase/cyclooxygenase (COX-2) activity in vitro
16. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs
17. Cyclooxygenases 1, and 2
18. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach
19. Cox-2-selective inhibitors: The new super aspirins
20. New insights into the role of COX 2 in inflammation
21. Peroxisome proliferator activated receptor α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs
22. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-α, -β, and -γ in the adult rat
23. 4 pathway to inflammation control
24. Medical significance of peroxisome proliferator-activated receptors
25. Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity
26. PPAR γ agonists inhibit production of monocyte inflammatory cytokines
27. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
28. Down regulation of peroxisome proliferator-activated receptor γ expression by inflammatory cytokines and its reversal by thiazolidinediones
29. Activation of human aortic smooth muscle is inhibited by PPARα but not PPARγ activators
30. Functional domains of the human glucocorticoid receptor
31. Two cis-acting regulatory sequences in the peroxisome proliferator-responsive enhancer region of the rat acyl-CoA oxidase gene
32. Interaction of glucocorticoid analogs with the glucocorticoid receptor
33. Analysis of a tissue-specific enhancer: ARF6 regulates adipogenic gene expression
34. Fluorometric assay for rat liver peroxisomal fatty acyl-coenzyme A oxidase activity
35. Stereoselective effects of chiral clofibric acid analogs on rat peroxisome proliferator-activated receptor alpha activation and peroxisome fatty acid β-oxidation
36. Uptake of adenosine and adenosine diphosphate by human blood platelets
37. Preparation of suspensions of washed platelets in humans
38. Computerized aggregation instruments: A highly efficient and versatile system for acquisition, quantitation, presentation and management of platelet aggregation data
39. Behavior of endogenous and newly absorbed serotonin in the platelet release reaction
40. Stereo-dependent inhibition of human platelet function by optical isomers of trimetoquinol
41. Differential inhibition of prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs
42. Aspirin-like drugs may block pain independently of prostaglandin synthesis inhibition
43. Prostaglandins and platelets
44. The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological consequences
45. PGH synthase isoenzyme selectivity: The potential for safer non-steroidal anti-inflammatory drugs
46. Peroxisome proliferator-activated receptor: Insight into multiple cellular functions
47. Update on the mechanism of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer
48. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs
49. Pharmacological peroxisome proliferator-activated receptor-γ ligands: Emerging clinical indications beyond diabetes
50. Roles of PPARs in health and disease